Laurus Labs Limited
American Funds (Capital Group) cut its stake in Laurus Labs from 7.05% to 5.79%, selling 67,80,688 shares.
A research-driven pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients for anti-retroviral, oncology, cardiovascular, and gastroenterology therapies with global leadership positions in select segments. Laurus Labs operates multiple facilities approved by major regulatory agencies including USFDA, WHO-Geneva, EMA, and others. The company provides integrated contract manufacturing and development services to international pharmaceutical innovators across clinical development through commercial production stages.
India equity holdings of American Funds, the mutual fund family of Capital Group. Long-only, fundamentally driven strategy.